Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 22, 2026, 2:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2593–2616 of 17,854 matching trials from the live ClinicalTrials.gov search.
Conditions
Brain Cancer, Glioblastoma
Interventions
Standard Dose Bevacizumab, Low Dose Bevacizumab, Lomustine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Biliary Atresia
Interventions
Filgrastim
Drug
Lead sponsor
Holterman, Ai-Xuan, M.D.
Individual
Eligibility
14 Days to 180 Days
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Geographic Atrophy
Interventions
ACU-4429, Placebo
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
55 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK256073, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
20 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Anniston, Alabama • Miami, Florida • Miami Gardens, Florida + 1 more
Conditions
Medical Oncology
Interventions
Anetumab ravtansine (BAY94-9343), Itraconazole
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Santa Monica, California • Detroit, Michigan • St Louis, Missouri + 2 more
Conditions
Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
Interventions
Elranatamab, Daratumumab, Lenalidomide, autologous stem cell transplantation
Drug · Procedure
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
19 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
11
States / cities
Birmingham, Alabama • Denver, Colorado • Iowa City, Iowa + 8 more
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine, ActHIB, PedvaxHIB, Pediarix, Prevnar, M-M-R II, Varivax
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 15 Months
Enrollment
4,441 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
88
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 76 more
Terminated Phase 1 Interventional Results available

M3541 in Combination With Radiotherapy in Solid Tumors

NCT03225105
Conditions
Solid Tumors
Interventions
M3541, Palliative Radiotherapy (RT)
Drug · Radiation
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Indianapolis, Indiana • St Louis, Missouri • Hackensack, New Jersey + 2 more
Conditions
Healthy
Interventions
Seltorexant 40 mg, Seltorexant 20 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Obesity
Interventions
Standard Dose Group, Weight Based Group
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Completed Phase 2 Interventional Accepts healthy volunteers Results available

TIV and High Dose TIV in Subjects With Rheumatoid Arthritis

NCT01436370
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
COVID-19
Interventions
PF-07817883
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
6
States / cities
Anaheim, California • Garden Grove, California • Montclair, California + 2 more
Conditions
Restless Legs Syndrome
Interventions
GEn (XP13512/GSK1838262), Placebo
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Breast Abscess
Interventions
Standard of care breast abscess drainage, Methylene Blue, Lipid Emulsion, Insertion of optical fiber, Laser illumination, Photodynamic therapy
Procedure · Drug · Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Rochester, New York
Completed Phase 2Phase 3 Interventional Results available

Study of Efficacy of CDZ173 in Patients With APDS/PASLI

NCT02435173
Conditions
Common Variable Immunodeficiency (CVID), APDS / PASLI
Interventions
CDZ173, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Prostate Adenocarcinoma
Interventions
Osanetant
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Childhood Absence Epilepsy
Interventions
Cannabidiol Oral Solution
Drug
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
3 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
11
States / cities
Miami, Florida • Tampa, Florida • Atlanta, Georgia + 8 more
Conditions
Opioid Dependence, Acute Opioid Withdrawal Syndrome
Interventions
Lofexidine HCl, Placebo, Open Label Lofexidine HCL
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years and older
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
18
States / cities
Clovis, California • Escondido, California • San Diego, California + 15 more
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
Exicorilant, Enzalutamide, Placebo
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
6
States / cities
Scottsdale, Arizona • Detroit, Michigan • Basking Ridge, New Jersey + 3 more
Conditions
Gastro-Esophageal Junction Adenocarcinoma, Gastric Cancer
Interventions
Nab-paclitaxel 150 mg/m^2, Oxaliplatin 85 mg/m^2, 5-FU 1200 mg/m^2 x 2 D, Leucovorin 400 mg/m^2
Drug
Lead sponsor
Al B. Benson, III, MD
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
8
States / cities
Chicago, Illinois • Lake Forest, Illinois • Iowa City, Iowa + 4 more
Conditions
Colorectal Neoplasms
Interventions
Modified Bolus 5-FU/LV with Irinotecan, FOLFIRI + bevacizumab, miFL + bevacizumab, Infusional 5-FU/LV with Irinotecan, Oral Capecitabine with Irinotecan
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
141
States / cities
Birmgingham, Alabama • Birmingham, Alabama • Birmngham, Alabama + 123 more
Conditions
Chronic Lymphocytic Leukemia (CLL), Relapsed, Refractory
Interventions
EGFRt/19-28z/4-1BBL CAR T cells
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Urinary Bladder, Overactive
Interventions
Solifenacin succinate suspension
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
5 Years to 17 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Shreveport, Louisiana
Conditions
Carcinoma, Lymphoma
Interventions
Intravenous EZN-2968 (anti-HIF-1α LNA AS-ODN)
Drug
Lead sponsor
Enzon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania • Lubbock, Texas